AstraZeneca Pharmaceuticals LP
Boston R&D Site
35 Gatehouse Drive
Waltham
Massachusetts
02451
United States
Tel: 781-839-4000
Website: http://www.astrazeneca-us.com/
About AstraZeneca Pharmaceuticals LP
At AstraZeneca, science and patients are at the heart of everything we do. As one of the world’s leading biopharmaceutical companies, AstraZeneca operates in more than 100 countries, producing innovative medicines used by millions of patients worldwide. Our expertise spans the entire life-cycle of a medicine and we have a unique combination of capabilities in small molecules, biologics, immunotherapies and protein engineering.
With our North America Commercial Headquarters in Wilmington, DE; one of three global Research and Development (R&D) centers in Gaithersburg, MD; and other R&D, manufacturing and office locations across the country, AstraZeneca’s U.S. operations are integral to our global business and to our efforts to make a meaningful difference in healthcare.
Commitment to Patients Everything we do at AstraZeneca is driven by our commitment to improving the lives of patients – whether we’re working to reach more people with our medicines, applying distinctive science to developing the next generation of treatments or collaborating with others in the fight against disease.
We are focused on understanding and helping to meet the needs of people facing serious health challenges, and our skills and resources are concentrated on those therapy areas where we believe we can make the most difference: oncology; cardiovascular and metabolic disease; and respiratory, inflammatory and autoimmune disease. Alongside this, we remain active in infection, neuroscience and gastrointestinal disease through select opportunities.
Scientific Leadership At AstraZeneca, we push the boundaries of science to deliver medicines that transform the lives of people around the world. Globally, AstraZeneca’s research investment totaled more than $4 billion in 2013. At the end of 2013, we had 99 pipeline projects, including 85 in the clinical development phase and 14 either approved, launched or filed.
AstraZeneca’s Gaithersburg, MD campus is one of three global strategic R&D centers and home to MedImmune, the global biologics research and development arm of AstraZeneca. MedImmune is pioneering innovative research and exploring novel pathways across AstraZeneca’s key therapeutic areas – with a robust pipeline of more than 120 biologics, including more than 30 in clinical development.
In addition, AstraZeneca’s Boston R&D site in Waltham, MA employs hundreds of talented AstraZeneca researchers, scientists and support staff representing more than 30 nationalities – and serves as the company’s headquarters for small-molecule discovery research in North America and global infectious disease research, with an additional focus on oncology drug research.
Collaboration as a Way of Life We believe that some of the most exciting science comes from external collaborations. We have approximately 850 current industry and academic collaborations or partnerships around the world. By sharing new ideas and enabling scientific innovation to cross boundaries between companies, academia, government and nonprofit organizations, we can accelerate new ideas into innovative medicines. The AstraZeneca Open Innovation platform (www.openinnovation.astrazeneca.com) has been created to help us do just that.
Key Locations Worldwide Headquarters: Cambridge, UK North America Headquarters: 1800 Concord Pike Wilmington, Delaware 19850 Phone: 302-886-3000 North America Strategic R&D Center: Gaithersburg, MD
31 articles about AstraZeneca Pharmaceuticals LP
-
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex
7/22/2021
RedHill Biopharma Ltd. today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP ("AstraZeneca") and Nektar Therapeutics have entered into a settlement and license agreement with Apotex, Inc. resolving their patent litigation.
-
Upsher-Smith's Parent Company Enters Into Agreement With Astra to Manufacture And Market Migraine Medication in Japan
10/30/2017
Upsher-Smith today reported that Sawai has entered into an exclusive agreement with Astra to manufacture and market Zomig Tablets 2.5 mg and Zomig RM Tablets 2.5 mg, a migraine medication in Japan designed to melt quickly in the mouth.
-
New First-in-Pediatrics Trial At Children's Hospital Los Angeles To Test AstraZeneca Pharmaceuticals LP's Durvalumab For Certain Cancers
8/18/2016
-
Court Rejects Teva Pharmaceutical Industries Limited Appeal Over AstraZeneca Pharmaceuticals LP's Cholesterol Drug Crestor
12/2/2011
-
AstraZeneca Pharmaceuticals LP Release: Saturn Demonstrated Effect of Intensive Statin Treatment on Reducing Atherosclerosis
11/15/2011
-
AstraZeneca PLC (JOBS) Plans Local Job Cuts, Report Says
9/14/2009
-
AstraZeneca Pharmaceuticals LP Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
6/1/2009
-
Par Pharmaceutical, Inc. Halts Shipment of Budesonide Inhalation Suspension; Court Granted AstraZeneca Pharmaceuticals LP's Motion for Temporary Restraining Order Halting Sales of Teva Pharmaceutical Industries Limited's Generic Pulmicort Respules
11/21/2008
-
Statin Might Help More People Fight Heart Disease Than Thought, Brigham and Women's Hospital Study
11/10/2008
-
Graffinity Pharmaceuticals GmbH And AstraZeneca Pharmaceuticals LP Enter Into Multi-Target Drug Discovery Alliance
10/28/2008
-
PreMD Inc. Provides Corporate Update
9/16/2008
-
Phase III Study of Abbott Laboratories' Investigational TriLipix(TM) in Combination With AstraZeneca Pharmaceuticals LP's CRESTOR(R) Meets Primary Endpoints on Key Lipids
6/2/2008
-
Previous Findings Regarding Widely Used Asthma Treatment Challenged
1/14/2008
-
Study: Some Alzheimer's Drugs Very Risky
10/12/2006
-
AstraZeneca LP Release: New EXPLORER Results Show Patients Achieved Dramatic Reductions In C-Reactive Protein And LDL-C Levels With CRESTOR Combination Therapy
9/6/2006
-
The Day In Review: Shire Pharmaceuticals Wins Elaprase Approval
7/24/2006
-
The Day In Review: Merck & Co., Inc. Heats Up The Statin Wars
6/19/2006
-
AstraZeneca Pharmaceuticals LP Release: Novel Study Published In The New England Journal of Medicine Evaluates Effects Of ATACAND(R) (Candesartan Cilexetil) In Patients With Prehypertension
4/20/2006
-
AstraZeneca Foundation Patient Assistance Program Expands Eligibility For People With Medicare
4/18/2006
-
AstraZeneca Pharmaceuticals LP And University of Pennsylvania School of Medicine To Collaborate On Research
3/17/2006